[THE INVESTOR] Celltrion Healthcare, an affiliate of one of Korea’s leading biopharmaceutical firms, said on Jan. 3 that the market share of its biosimilar drug Truxima surpassed 35 percent in Europe during the third quarter.
The average market share of the biosimilar came to 36 percent in five European countries -- France, Italy, Germany, Spain and the United Kingdom -- during the July-September period, the health care company said in a press release.
The drug is based on Rituxan, originally developed by Swiss pharmaceutical giant Roche Holding, the Celltrion affiliate said.
After Truxima began selling in Britain following approval from a European regulator, the drug expanded to the 18 nations, including Germany, France and Italy. The drug is set to be sold in 22 European countries in the first half of this year.
By Song Seung-hyun and newswires (firstname.lastname@example.org)